Sygnature Discovery, a Nottingham, UK-based company which undertakes integrated drug discovery projects for pharmaceutical and biotechnology companies worldwide, is joining forces with RenaSci, another Nottingham firm that provides an integrated blend of consultancy and experimental services to help maximise research productivity and streamline drug development, to provide an integrated service to accelerate client projects in metabolic and CNS disorders from discovery into development.
Rob Jones, Executive Director at RenaSci, said: 'We have been collaborating with Sygnature for a number of years on projects which have delivered drug candidates, so we already have a well-established working relationship. Our strategic alliance combines the complementary skills and experience of RenaSci and Sygnature in metabolic diseases and CNS disorders. RenaSci shall continue to provide pre-clinical services and consultancy independently, but will also be able to actively contribute to Sygnature’s fully-integrated drug discovery capability.'
Simon Hirst, Sygnature’s CEO, added: 'Sygnature already has a long-term and close working relationship with RenaSci, which will be cemented through this alliance. It enables Sygnature Discovery to offer its customers a metabolic disease and CNS-focused integrated drug discovery package where novel compounds can be designed, synthesised and tested in vitro at Sygnature and then assessed in vivo at RenaSci in disease-relevant models.'
